Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling

Authors:

Abstract
A major obstacle to identifying improved treatments for pediatric low-grade brain tumors (gliomas) is the inability to reproducibly generate human xenografts. To surmount this barrier, we leveraged human induced pluripotent stem cell (hiPSC) engineering to generate low-grade gliomas (LGGs) harboring the two most common pediatric pilocytic astrocytoma-associated molecular alterations, NF1 loss and KIAA1549:BRAF fusion. Herein, we identified that hiPSC-derived neuroglial progenitor populations (neural progenitors, glial restricted progenitors and oligodendrocyte progenitors), but not terminally differentiated astrocytes, give rise to tumors retaining LGG histologic features for at least 6 months in vivo. Additionally, we demonstrated that hiPSC-LGG xenograft formation requires the absence of CD4 T cell-mediated induction of astrocytic Cxcl10 expression. Genetic Cxcl10 ablation is both necessary and sufficient for human LGG xenograft development, which additionally enables the successful long-term growth of patient-derived pediatric LGGs in vivo. Lastly, MEK inhibitor (PD0325901) treatment increased hiPSC-LGG cell apoptosis and reduced proliferation both in vitro and in vivo. Collectively, this study establishes a tractable experimental humanized platform to elucidate the pathogenesis of and potential therapeutic opportunities for childhood brain tumors.
Funding Information
  • National Cancer Institute (R50-CA233164-01)
  • Siteman Cancer Center (pre-pilot grant)
  • Pediatric Brain Tumor Foundation (P20-00873)
  • Ian's Friends Foundation (grant)
  • National Institute of Neurological Disorders and Stroke (1-R35-NS07211-01)
  • National Cancer Center (P30-CA091842)
  • National Eye Institute (P30EY002687)

This publication has 70 references indexed in Scilit: